Market Place
Sourcing Support
Cingulate`s Shane Schaffer Joins Big Biz Show Cast
09 Oct 2024 //
GLOBENEWSWIRE
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
12 Sep 2024 //
GLOBENEWSWIRE
Cingulate to Participate in Benzinga All Live Access Event
27 Aug 2024 //
GLOBENEWSWIRE
Cingulate Announces Adjournment of Special Meeting
23 Aug 2024 //
GLOBENEWSWIRE
Cingulate Gets European Patent For ADHD Treatment Asset CTx-1301
15 Aug 2024 //
GLOBENEWSWIRE
Cingulate Reports Q2 2024 Results And Development Milestones
13 Aug 2024 //
GLOBENEWSWIRE
Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
28 Jun 2024 //
GLOBENEWSWIRE
Cingulate Achieves Milestone in CTx-1301 ADHD Drug Development for FDA Clearance
25 Jun 2024 //
GLOBENEWSWIRE
Cingulate and ADHD Expert Participate in Benzinga All Live Access Event
25 Jun 2024 //
GLOBENEWSWIRE
FDA Clears Cingulate To File For CTx-1301 ADHD Approval
21 May 2024 //
GLOBENEWSWIRE
Cingulate Q1 2024 Financials, Clinical/Business Update
08 May 2024 //
GLOBENEWSWIRE
Cingulate`s Werth, Schaffer Featured on Benzinga All Access
30 Apr 2024 //
GLOBENEWSWIRE
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
16 Apr 2024 //
GLOBENEWSWIRE
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
01 Apr 2024 //
GLOBENEWSWIRE
Cingulate to Participate in Benzinga All Live Access Event
19 Mar 2024 //
GLOBENEWSWIRE
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
29 Jan 2024 //
GLOBENEWSWIRE
Cingulate Announces Pricing of $4.0 Million Public Offering
11 Sep 2023 //
GLOBENEWSWIRE
Werth Family Investment Associates Converts $5.8 Million of Debt
08 Sep 2023 //
GLOBENEWSWIRE
Cingulate Inc. Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Cingulate to Participate in the Healthcare Virtual Conference Part II
14 Jun 2023 //
GLOBENEWSWIRE
Cingulate Completes PIII Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
08 Jun 2023 //
GLOBENEWSWIRE
Cingulate to Present at 13th Annual LD Micro Invitational
25 May 2023 //
GLOBENEWSWIRE
Cingulate, Indegene to Participate in Benzinga All Live Access Event
12 May 2023 //
GLOBENEWSWIRE
Cingulate to Participate in Benzinga All Live Access Event
14 Apr 2023 //
GLOBENEWSWIRE
Cingulate Completes First Cohort of Phase 3 Trial of CTx-1301
04 Apr 2023 //
GLOBENEWSWIRE
Cingulate and Indegene Announce Agreement for ADHD Candidate CTx-1301
13 Mar 2023 //
GLOBENEWSWIRE
Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
10 Mar 2023 //
GLOBENEWSWIRE
Cingulate Announces Positive Results from Fed/Fast Study of CTx-1301 for ADHD
23 Feb 2023 //
GLOBENEWSWIRE
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301
04 Jan 2023 //
GLOBENEWSWIRE
Cingulate to Participate in Benzinga All Live Access Event
30 Nov 2022 //
GLOBENEWSWIRE
Cingulate Inc. Reports 3Q 2022 Financial Results and Provides Clinical Update
14 Nov 2022 //
GLOBENEWSWIRE
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301
01 Nov 2022 //
GLOBENEWSWIRE
Cingulate, Societal CDMO Enter Mfg. Pact for ADHD Drug
25 Oct 2022 //
CONTRACTPHARMA
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
24 Oct 2022 //
GLOBENEWSWIRE
Cingulate to Present at LD Micro Investor Conference
20 Oct 2022 //
GLOBENEWSWIRE
Cingulate posts clinical data on triple-release anxiety tablet
20 Sep 2022 //
FIERCEPHARMA
Cingulate Inc. Reports Q2 2022 Rusult and Provides Clinical and Business Update
11 Aug 2022 //
GLOBENEWSWIRE
Cingulate Completes CTx-2103 Human Formulation Study for Anxiety Disorders
23 Jun 2022 //
GLOBENEWSWIRE
Cingulate to Present at Diamond Equity Research 2022
17 Jun 2022 //
GLOBENEWSWIRE
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga Event
02 Jun 2022 //
GLOBENEWSWIRE
Cingulate Announces Complete Enrollment of CTx-2103 in Anxiety Disorders
24 May 2022 //
GLOBENEWSWIRE
Cingulate to Present at H.C. Wainwright Global Investment Conference
18 May 2022 //
GLOBENEWSWIRE
Cingulate Inc. Reports First Quarter 2022 Results
12 May 2022 //
GLOBENEWSWIRE
Immuneering Reports Q4 and FY 2021 Financial Resultss
10 Mar 2022 //
GLOBENEWSWIRE
Cingulate Provides 2022 Clinical Plan for CTx-1301 in ADHD
08 Feb 2022 //
GLOBENEWSWIRE
Cingulate Inc. Announces Closing of Initial Public Offering
10 Dec 2021 //
GLOBENEWSWIRE
Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering
07 Dec 2021 //
GLOBENEWSWIRE
How a busy year for biotech IPOs measures up at the three-quarter mark
04 Oct 2021 //
BIOPHARMADIVE
How a busy year for biotech IPOs measures up at the three-quarter mark
04 Oct 2021 //
BIOPHARMADIVE
ADHD drug developer Cingulate sets terms for $50 million IPO
27 Sep 2021 //
RENAISSANCECAPITAL
ADHD drug developer Cingulate files for a $58 million IPO
09 Sep 2021 //
RENAISSANCE CAPITAL
Cingulate CEO: $7.5M fundraising round will help drive pharma growth in KC
23 Mar 2020 //
BIZJOURNAL
BDD Pharma and Cingulate Therapeutics Announce License Agreement
10 Sep 2018 //
PR NEWSWIRE
